🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The NADINA trial of neoadjuvant ipi/nivo vs adjuvant nivo in melanoma is a plenary #ASCO24 . Shorter periods of therapy in responders (neoadjuvant alone) is an important question. Neoadjuvant nivo didn’t work in RCC (PROSPER). PACIFIC2 struggled in lung ascopubs.org/doi/10.1200/JC…

New post of the "Friday's GEM" section of the Drug Development Letter ! A seminal trial in breast cancer led by George W Sledge MD Check it out❗️drugdevletter.com👇

New findings from IU Simon Comprehensive Cancer Center researchers indicate that salvage HDCT and PBSCT is an active combination in patients who have relapsed primary mediastinal nonseminomatous germ cell tumors with curative potential and prolonged survival. acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… OncoAlert

Dear Colleagues, The OncoAlert 🚨Network Presents OUR Picks of TOP 🔟Abstracts to be Presented at #ASCO24 for #Melanoma This List Curated by: #OncoAlertAF Leads : Annie Wong 黃毅敏 🇳🇿 Gil Morgan, MD 🇺🇸 and OncoAlert #Melanoma Faculty Allison Betof Warner, MD, PhD 🇺🇸 TOP 11 Abstracts Neoadjuvant

🚨 NADINA is positive NADINA is the first phase 3 trial that evaluates neoadj ICI against SOC in melanoma, and is also the first phase 3 trial in oncology evaluating a neoadj regimen of ICI alone. Neoadj IPI+NIVO followed by response-driven adj tx should be new SOC #ASCO24

OncoAlert Look at those curves!!! 67% relative risk reduction! Favors ipi/nivo in all subgroups. 59% major pathological response. Incredible 👏👏👏

Great opportunity!

Expertly presented by Professor Georgina Long AO (Bluesky @gvlongphdmd) impressive data updating the INMC pooled analysis with 818 pts confirming that MPR w ICI predicts for over 90% 3-year EFS & RFS, combination ICI with most impressive MPR rates. Multi center international collaborations provides robust &

Update on NADINA by Minke Lucas consistent & impressive DMFS data w neoadjuvant low dose ipi+nivo, benefit for RFS carrying into DMFS & perhaps w enough follow up will see an impact on OS. Neoadjuvant ICI combination should become SOC for pts w bulky locoregional melanoma

Among patients who had been alive and progression-free at 3 years (1/3 of the IPI/Nivo arm), 10-year melanoma-specific survival was 96%. Incredible! 🏆

No post-recurrence data is so concerning. again, the comparison is informative: ➡️AMBASSADOR (adj pembro), accrual till Aug 21 , median FU=37Mo , post-recurrence available ➡️NIAGARA (periop durva), accrual till July 21, median (EFS) FU=42Mo, NO post-recurrence data.

Standing room only for GCT session. Happy to see the enthusiasm to review new data and trial landscape. Time to finish the mission in testes/GCT! Great talks by Axel Heidenreich, Nabil Adra and Dr. Darren Feldman #GU25

Thoughtful discussion by Clint Cary, MD MPH MBA of Indiana University Department of Urology regarding surgery in early metastatic seminoma. IU Simon Comprehensive Cancer Center Testicular Cancer

As a leading institution in the management of germ cell tumors, Indiana University Hematology/Oncology Fellowship fellows work with IU Simon Comprehensive Cancer Center faculty leading the field in treatment and survivorship. Outstanding GU group and Urology group at IU! Nabil Adra Jennifer King Tareq Salous IU_UroOnc

Management of testis cancer course at #AUA25 led by IU team Clint Cary, MD MPH MBA Nabil Adra and Dr. Masterson! IU Simon Comprehensive Cancer Center

Congrats to chief fellow Noah Richardson for their Conquer Cancer, the ASCO Foundation Young Investigator Award investigating novel prostate cancer therapeutics and our brilliant faculty member Misty Dawn Shields Career Development Award in lung cancer. #ASCO2025 is off to a great start! IU Simon Comprehensive Cancer Center

Indiana University reception at #ASCO2025 . Proud to work with a fantastic group of past, present, and future colleagues IU Simon Comprehensive Cancer Center Indiana University Hematology/Oncology Fellowship IU_UroOnc Rafat Abonour Christopher Sweeney, MBBS Noah Richardson Robin Zon, MD, FACP, FASCO Ahmad Al-Hader Greg Durm Nasser Hanna Jennifer Schwartz MD FASCO

The most practice changing trial from #ASCO25 is now live on NEJM .If this was a drug, this would be approved today. Globally relevant and low-cost intervention that is not only delaying relapse but actually improving survival. Perfect case example of a #cancergroundshot trial.

Appreciate all the support and guidance from a friend and mentor Nabil Adra over the years. It’s been a wonderful #ASCO2025 and looking forward to joining a great GU group! Tareq Salous Jennifer King IU Simon Comprehensive Cancer Center

Tour de force by Larry Einhorn going over Pitfalls in the Management of Metastatic GCT and wisdom from over 50 years of expertise in treating testicular cancer. And yes the reference for hCG decline was from Robin Zon, MD, FACP, FASCO from IU fellowship IU Simon Comprehensive Cancer Center Indiana University Hematology/Oncology Fellowship Indiana University Department of Urology